Equities

Mochida Pharmaceutical Co Ltd

Mochida Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,260.00
  • Today's Change30.00 / 0.93%
  • Shares traded23.70k
  • 1 Year change-5.09%
  • Beta0.2804
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Mochida Pharmaceutical Co Ltd share price to rise to 5,200.00 in the next year from the last price of 3,260.00.
High59.5%5,200.00
Med59.5%5,200.00
Low59.5%5,200.00

Dividends

Dividend information is not available for Mochida Pharmaceutical Co Ltd.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in JPY

Mochida Pharmaceutical Co Ltd reported annual 2024 earnings of 126.80 per share on May 13, 2024.
Average growth rate+12.31%
More ▼

Revenue history & estimates in JPY

Mochida Pharmaceutical Co., Ltd. had 1st quarter 2025 revenues of 25.41m. This was 2.67% above the prior year's 1st quarter results.
Average growth rate+1.24%
Mochida Pharmaceutical Co., Ltd. had revenues for the full year 2024 of 102.89m. This was 0.36% below the prior year's results.
Average growth rate+0.38%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.